MICU Vicuron Pharmaceuticals (MM)

Vicuron Pharmaceuticals to Present at the Needham & Company Biotechnology Conference KING OF PRUSSIA, Pa., June 14 /PRNewswire-FirstCall/ -- Vicuron Pharmaceuticals Inc. (NASDAQ:MICU) today announced that Dov A. Goldstein, M.D., Executive Vice President and CFO, will present at the Needham & Company Third Annual Biotechnology Conference at 10:30 a.m. Eastern Time on Thursday, June 17, 2004 at The New York Palace Hotel in New York, N.Y. To access the live audio broadcast or the subsequent archived recording log on to http://www.vicuron.com/ and click on the investor relations section. Please connect to the website several minutes prior to the start of the webcast to ensure adequate time for any software download that may be necessary. The live broadcast will be archived for 30 days. About Vicuron Vicuron Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing vital medicine for seriously ill patients in North America and Europe. The company received an approvable letter for its lead product anidulafungin in May 2004. The company's other lead product, dalbavancin, a novel intravenous antibiotic for the treatment of serious Gram-positive infections, is in Phase III clinical trials. The company's versatile research engine integrates industry-leading expertise in functional genomics, natural products discovery, mechanism-based drug design and combinatorial and medicinal chemistry. These approaches are yielding promising novel and next-generation compounds, many of which are in the later stages of preclinical development. In addition, the company has research and development collaborations with leading pharmaceutical companies, such as Pfizer and Novartis. Forward-Looking Statements This news release and the presentation contain forward-looking statements that predict or describe future events or trends. The matters described in these forward-looking statements are subject to known and unknown risks, uncertainties and other unpredictable factors, many of which are beyond Vicuron's control. Vicuron faces many risks that could cause its actual performance to differ materially from the results predicted by its forward-looking statements, including the possibilities that clinical trials and the results thereof might be delayed, that the timing of the filing of any new drug application might be delayed, that subsequent clinical trials might indicate that a product candidate is unsafe or ineffective, that any filed new drug application may not be approved, that ongoing proprietary and collaborative research might not occur or yield useful results, that a third party may not be willing to license our product candidates on terms acceptable to us or at all, that competitors might develop superior substitutes for their products or market them more effectively, that a sales force may not be developed as contemplated and that one or more of its product candidates may not be commercialized successfully. The reports that Vicuron files with the U.S. Securities and Exchange Commission contain a fuller description of these and many other risks to which Vicuron is subject. Because of those risks, Vicuron's actual results, performance or achievements may differ materially from the results, performance or achievements contemplated by its forward-looking statement. The information set forth in this news release and the presentation represent management's current expectations and intentions. Vicuron assumes no responsibility to issue updates to the forward-looking matters discussed in this news release. DATASOURCE: Vicuron Pharmaceuticals Inc. CONTACT: Hala Bashir of WeissCom, +1-212-204-2080, for Vicuron Pharmaceuticals Inc. Web site: http://www.vicuron.com/

Copyright